Target-directed cancer: protein-ligand interactions
Drug Target Review
NOVEMBER 1, 2023
In 2001, he joined Astex Pharmaceuticals in Cambridge where he became an expert in fragment-based drug discovery working on diabetes, thrombotic and oncology drug targets. He received his undergraduate degree in Chemistry and PhD in structural biology at the University of Groningen in the Netherlands.
96 
Let's personalize your content